ID   PNG1_PANCL              Reviewed;          12 AA.
AC   C0HL84;
DT   20-JUN-2018, integrated into UniProtKB/Swiss-Prot.
DT   20-JUN-2018, sequence version 1.
DT   25-MAY-2022, entry version 9.
DE   RecName: Full=Panurgin 1 {ECO:0000303|PubMed:23483218};
DE            Short=PNG-1 {ECO:0000303|PubMed:23483218};
OS   Panurgus calcaratus (Solitary bee).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Apoidea;
OC   Andrenidae; Panurginae; Panurgini; Panurgus.
OX   NCBI_TaxID=156354 {ECO:0000303|PubMed:23483218};
RN   [1] {ECO:0000305}
RP   PROTEIN SEQUENCE, FUNCTION, MASS SPECTROMETRY, AMIDATION AT LYS-12, AND
RP   MUTAGENESIS OF TRP-3; ILE-6; LEU-7; ILE-10 AND ILE-11.
RC   TISSUE=Venom {ECO:0000303|PubMed:23483218};
RX   PubMed=23483218; DOI=10.1007/s00726-013-1482-4;
RA   Cujova S., Slaninova J., Monincova L., Fucik V., Bednarova L., Stokrova J.,
RA   Hovorka O., Voburka Z., Straka J., Cerovsky V.;
RT   "Panurgines, novel antimicrobial peptides from the venom of communal bee
RT   Panurgus calcaratus (Hymenoptera: Andrenidae).";
RL   Amino Acids 45:143-157(2013).
CC   -!- FUNCTION: Antimicrobial peptide active against Gram-positive bacteria
CC       M.luteus (MIC=1.5 uM), B.subtilis (MIC=1.3 uM) and S.aureus (MIC=10.6
CC       uM), against Gram-negative bacteria E.coli (MIC=3.7 uM) and
CC       P.aeruginosa (MIC=51.7 uM) as well as against yeast C.albicans (MIC=7.3
CC       uM). Has weak hemolytic activity against human erythrocytes. Probably
CC       acts by disrupting membranes of target cells.
CC       {ECO:0000269|PubMed:23483218}.
CC   -!- SUBCELLULAR LOCATION: Target cell membrane
CC       {ECO:0000305|PubMed:23483218}. Secreted {ECO:0000269|PubMed:23483218}.
CC   -!- MASS SPECTROMETRY: Mass=1403.7; Method=Electrospray;
CC       Evidence={ECO:0000269|PubMed:23483218};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0051715; P:cytolysis in another organism; IDA:UniProtKB.
DR   GO; GO:0050832; P:defense response to fungus; IDA:UniProtKB.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IDA:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IDA:UniProtKB.
DR   GO; GO:0044179; P:hemolysis in another organism; IEA:UniProtKB-KW.
DR   GO; GO:0031640; P:killing of cells of another organism; IDA:UniProtKB.
DR   GO; GO:0051673; P:membrane disruption in another organism; IDA:UniProtKB.
PE   1: Evidence at protein level;
KW   Amidation; Antibiotic; Antimicrobial; Cytolysis; Direct protein sequencing;
KW   Fungicide; Hemolysis; Membrane; Secreted; Target cell membrane;
KW   Target membrane.
FT   PEPTIDE         1..12
FT                   /note="Panurgin 1"
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT                   /id="PRO_0000444565"
FT   MOD_RES         12
FT                   /note="Lysine amide"
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         3
FT                   /note="W->K: Virtually complete loss of antimicrobial and
FT                   hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         6
FT                   /note="I->A: Complete loss or severe reduction of
FT                   antimicrobial activity and loss of hemolytic activity; when
FT                   associated with A-10 and A-11."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         6
FT                   /note="I->K: Complete loss or severe reduction of
FT                   antimicrobial activity. Loss of hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         6
FT                   /note="I->L: Increased hemolytic activity; when associated
FT                   with L-10 and L-11."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         7
FT                   /note="L->K: Complete loss or severe reduction of
FT                   antimicrobial activity. Loss of hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         10
FT                   /note="I->A: Complete loss or severe reduction of
FT                   antimicrobial activity and loss of hemolytic activity; when
FT                   associated with A-6 and A-11."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         10
FT                   /note="I->K: Complete loss or severe reduction of
FT                   antimicrobial activity. Loss of hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         10
FT                   /note="I->L: Increased hemolytic activity; when associated
FT                   with L-6 and L-11."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         11
FT                   /note="I->A: Complete loss or severe reduction of
FT                   antimicrobial activity and loss of hemolytic activity; when
FT                   associated with A-6 and A-10."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         11
FT                   /note="I->K: Severe reduction of antimicrobial activity.
FT                   Loss of hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:23483218"
FT   MUTAGEN         11
FT                   /note="I->L: Increased hemolytic activity; when associated
FT                   with L-6 and L-10."
FT                   /evidence="ECO:0000269|PubMed:23483218"
SQ   SEQUENCE   12 AA;  1406 MW;  C1E8C7F99F37205D CRC64;
     LNWGAILKHI IK